|Bid||1,334.80 x 0|
|Ask||1,335.20 x 0|
|Day's range||1,324.40 - 1,346.00|
|52-week range||1,324.40 - 1,857.00|
|Beta (5Y monthly)||0.34|
|PE ratio (TTM)||10.06|
|Earnings date||28 Oct 2020|
|Forward dividend & yield||0.76 (5.51%)|
|Ex-dividend date||13 Aug 2020|
|1y target est||1,644.50|
GlaxoSmithKline (GSK) closed at $35.35 in the latest trading session, marking a -1.91% move from the prior day.
GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by mid-stage trial results. RSV vaccine development has been fraught with setbacks for decades but the pharma industry is gearing up to bring a first inoculation to market over the next few years. GSK said a Phase I/II trial with about 1,000 healthy adults aged 60-80 showed that the vaccine prompted a "robust" increase in antibodies and immune cells one month after injection, indicating a stimulated immune system.
What happened Shares of Surface Oncology (NASDAQ: SURF) were soaring 19.1% higher as of 3:26 p.m. EDT on Monday. The big jump came after StreetInsider reported that Surface Oncology has hired an investment bank to explore selling the company, with GlaxoSmithKline (NYSE: GSK) expressing interest in acquiring the biotech.